Skip to search formSkip to main contentSkip to account menu

olprinone

Known as: 1,2-dihydro-6-methyl-2-oxo-5-(imidazo(1,2-a)pyridin-6-yl)-3-pyridinecarbonitrile 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Endothelial barrier function is an essential and tightly regulated process that ensures proper compartmentalization of the… 
2012
2012
Olprinone, a specific phosphodiesterase III inhibitor, and corforsin daropate, a direct adenylate cyclase activator, are now… 
2010
2010
PurposeSplanchnic artery occlusion (SAO) shock is a severe form of circulatory shock produced by ischemia and reperfusion of the… 
2005
2005
Activated leukocytes are implicated in development of ischemia/reperfusion (I/R)-induced organ injuries. Phosphodiesterase 3… 
2003
2003
Cerebral blood flow (CBF) is reduced in heart failure (HF). For the treatment of acute HF, a phosphodiesterase-3 inhibitor… 
Review
2002
Review
2002
Olprinone is a newly developed phosphodiesterase III inhibitor characterized by several properties. First, olprinone has positive… 
Highly Cited
2001
Highly Cited
2001
Background—Phosphodiesterase III inhibitors (PDEIII-Is) improve the hemodynamic status of heart failure via inotropic… 
2000
2000
Objective: To measure the hepatic venous oxygen saturation in patients after cardiac surgery and to compare the effects of… 
2000
2000
Background: Increasing evidence indicates that amrinone, a phosphodiesterase fraction III (PDE‐III) inhibitor, has relative… 
Highly Cited
1999
Highly Cited
1999
The effect of topical administration of phosphodiesterase (PDE) 3 inhibitors on the airway is not clear. In order to examine the…